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Introduction
In the early 20th century, after extensive studies of the 
ovine fetal circulation, Sir Joseph Barcroft (1872-1947) 
postulated that the environment in which the human 
fetus develops would be comparable to that likely 
endured by an adult on the summit of Mount Everest 
[1,2]. He termed this intriguing hypothesis ‘Everest
in utero’ and proposed that to survive the hypoxic uterine 
environ  ment the fetus must develop elaborate physio-
logical strategies comparable to those seen in climbers 
ascending the great Himalayan peaks.
In 2007, four climbers descending from the summit of 
Mount Everest (8,848 meters) took arterial blood gases 
from one another at 8,400 meters above sea level. Th  eir 
mean arterial partial pressure of oxygen (PaO2)  was 
3.28 kPa (24.6 mm Hg) with a mean calculated arterial 
oxygen saturation (SaO2) of 54% while they rested with-
out supplemental oxygen [3]. Among this group, one 
individ  ual had a PaO2 of 2.55  kPa (19.1  mm  Hg), the 
lowest PaO2 ever reported in an adult human. So how far 
removed from intrauterine life were these measurements, 
and do climbers exhibit, as does the fetus, physiological 
strate  gies that may beneﬁ   t the similarly hypoxemic 
critically ill patient?
From Barcroft’s sheep to mice and men
Th   e overwhelming challenge for a developing fetus is its 
complete reliance on the maternal circulation for oxyge-
nation via placental transfer. Th  e fetus therefore com-
petes with other maternal organs for a share of the 
systemic oxygen delivery such that increased demand 
from other maternal tissues could be detrimental to the 
fetal circulation. Extrapolations from animal studies 
suggest that human fetal PaO2 is between 2.5 and 3.5 kPa 
[4,5]. Th  us,  Barcroft’s  ‘Everest  in utero’ was a remarkably 
accurate prediction given the limited data available to 
him at the turn of the last century. Table  1 compares 
measurements that contribute to oxygen carriage in the 
fetus, the typical adult male, and climbers acclimatized to 
high altitude near the summit of Mount Everest. It seems 
an astonishing coincidence that the highest point on the 
Earth’s surface, the limit of human tolerance of hypox-
emia [6], is analogous to life in utero. Despite this degree 
of hypoxemia in utero, there is little evidence that 
anaerobic metabolism is a dominant source of fetal 
energy [7], suggesting that this level of fetal oxygenation 
is suﬃ   cient for tissue requirements.
Th  e fetus has negligible ability to increase systemic 
oxygen delivery so instead must initiate mechanisms that 
maximize the use of available oxygen supplies. Following 
an acute reduction in oxygen delivery, fetal tissue oxygen 
extraction increases to compensate until delivery falls 
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© 2010 BioMed Central Ltdbelow approximately 50% of normal [8]. Th   is increase in 
tissue oxygen extraction acts as a buﬀ  er before cellular 
oxygen consumption begins to fall, and the threshold of 
this consumption varies widely between diﬀ  erent organs 
[9]. Once tissue oxygen extrac  tion is maximal, there 
follows a marked decrease in fetal movement, particularly 
breathing eﬀ  ort and forelimb activity [10,11]. Cessation 
of excessive movement results in a reduced oxygen 
consumption, as demonstrated by the administration of 
neuromuscular blocking agents in experimental models 
[12]. Reduced activity in response to fetal hypoxic 
distress is used for the biophysical proﬁ  le as part of an 
objective antepartum assessment in high-risk obstetric 
cases [13]. Th  ough of clear beneﬁ   t during a hypoxic 
event, this strategy is by no means a lasting solution for a 
chronic reduction in oxygen availability. Th  e primary 
energy-consuming process in the developing fetus is 
growth. Within several hours of reduced fetal oxygen 
delivery, protein synthesis begins to decline, reducing 
systemic oxygen consumption [14]. Th  is sacriﬁ  ce in the 
battle to maintain equilibrium of oxygen ﬂ  ux will cause 
intrauterine growth retardation so that survival will be at 
the cost of low birth weight and the possibility of organ 
pathology. Of note, chronic maternal hypoxia due to 
residence at high altitude is associated with reduced birth 
weight from restricted fetal growth during the third 
trimester [15]. Th   us, fetal survival is ensured by entering 
a period of hibernation-like existence in which oxygen-
consuming processes are downregulated in order to avoid 
anaerobic respiration. Clearly, there will be a threshold 
below which this strategy leads to irreversible organ 
damage.
Transition from uterine to atmospheric life involves the 
loss of mechanisms imperative for fetal survival but 
redundant in the relatively oxygen-rich air ex utero. To 
facilitate this, the lungs supervene over the placenta as 
the gas exchange surface, and there is anatomical 
redistribution of blood ﬂ  ow. Within weeks, the hemo-
globin concentration of the neonate slowly declines 
and  production of fetal hemoglobin (HbF), which 
possesses considerably greater aﬃ   nity for oxygen than 
does adult hemoglobin, ceases. Yet these and other 
mechanisms would surely be advantageous to adults 
during hypox  emic events. Th   e retention of life-sustaining 
fetal pheno  mena was ﬁ  rst demonstrated by the French 
physiologist Paul Bert some 140 years ago. Bert observed 
that newborn rats, when submersed in water, maintained 
persistent respiratory movements for up to 30 minutes, 
yet at 20 days of age, similar rats ceased to breathe after 
only 90 seconds [16]. It is feasible that the fetus, having 
developed in an environment with such limited oxygen 
availability, retains a degree of ‘acclimatization’ in 
neonatal life. Th  e prolonged hypoxemia in utero may 
serve as a time of intense ‘hypoxic preconditioning’ that 
provides a degree of protection from untoward obstetric 
catastrophes. However, as with climbers returning from 
the mountains, this acclimatization eﬀ  ect subsides with 
time, as shown by reduced resistance to hypoxia with 
increasing neonatal age.
Historically, life on Earth has also been one of extreme 
hypoxia. Th   e Earth was formed approximately 4.6 billion 
years ago and the earliest life-forms appeared soon after 
the planet’s period of heavy bombardment from meteor-
ites, 4 billion years ago. At that time, the atmosphere 
consisted of gases released from within the Earth’s crust, 
primarily nitrogen, carbon dioxide, water vapor, and 
hydrogen, the last of which was light enough to escape 
the Earth’s gravitational force. To the primitive anaerobic 
prokaryotes that ﬁ  rst inhabited the Earth, even traces of 
oxygen were highly toxic. Th  rough the photochemical 
destruction of water vapor, releasing oxygen and 
hydrogen, and then photosynthesis by cyanobacteria, the 
concentration of oxygen in the atmosphere rose and 
organisms were forced to adapt to shield themselves from 
its destructive power. Two billion years ago, a process 
known as eukaryotic endosymbiosis occurred in which 
mitochondria, evolved from a strain of purple bacteria, 
were engulfed by prokaryotic cells but retained their 
Table 1. Values pertinent to arterial oxygen carriage in the term fetus, male high-altitude climbers at 8,400 meters 
on Mount Everest, and typical adult male
  Term fetus  Climbers at 8,400 metersa  ‘Typical’ adult male
PaO2, kPa  2.5-3.5  3.28  13.3
SaO2, percentage  65  54  98
PaCO2, kPa  5.3-6.6  1.77  4.7-6.0
pH 7.25-7.35  7.53  7.35-7.45
Hb, g/dL  16.6  19.3  15.0
P50, kPa  2.5  3.6  3.5
CaO2, mL/L  150  145  200
aGrocott and colleagues [3]. CaO2, arterial oxygen content; Hb, hemoglobin concentration; P50, the arterial partial pressure of oxygen at which 50% of hemoglobin is 
saturated with oxygen; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen; SaO2, arterial oxygen saturation.
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hypoxic sanctuary for the anaerobic-seeking mitochon-
dria and a source of energy for the host cell, in the form 
of ATP, which allowed the development of eukaryotic 
characteristics and eventually multicellular aerobic life.
Our understanding of the human response to hypoxia 
has developed considerably since Barcroft’s day. Th  e 
heterodimeric protein hypoxia-inducible factor 1 (HIF-1) 
plays a central role in maintaining oxygen homeostasis. 
Cellular hypoxia results in reduced degradation by prolyl 
hydroxylase (PHD) and an exponential rise of the HIF-1α 
subunit, which combines with the constitutively expres-
sed HIF-1β subunit to form the active transcription 
factor. Th   is triggers upregulation of erythropoietin, 
angiogenic factors, and vasoactive mediators to improve 
oxygen delivery while induction of glycolytic enzymes 
permits continued energy production when oxygen for 
oxidative phosphorylation is scarce. Additionally, HIF-1 
depresses mitochondrial oxygen consumption and im-
proves the eﬃ   ciency of energy production within mito-
chondria [17,18]. During chronic fetal hypoxia, levels of 
HIF-1α are signiﬁ  cantly increased [19] while a deﬁ  ciency 
of either the α or β subunits in murine models is 
incompatible with embryonic life [20].
Another component of an individual’s ‘hypoxic 
response ﬁ  ngerprint’ is the seemingly paradoxical mito-
chon  drial production of reactive oxygen species (ROS) by 
enzymes of the respiratory chain when oxygen is scarce 
[21]. Elevated concentrations of ROSs have been detected 
in the cord blood of profoundly hypoxic neonates at birth 
[22]. Th  ese highly reactive molecules, if left unchecked, 
can cause extensive cellular oxidative damage and apop-
tosis. However, mitochondrial ROSs are also required 
during adaptation to hypoxia as they promote transcrip-
tion via HIF-1 [23] with concomitant negative feedback 
from HIF-1 attenuating ROS generation [24]. ROS pro-
duc  tion is also governed partly by uncoupling proteins 
(UCPs) on the inner mitochondrial membrane, allowing 
a leak of protons without the generation of energy [25]. 
Th  us, ROSs and UCPs act together to initiate cellular 
signaling during cellular hypoxia. Th  is contends the 
liberal use of antioxidants in hypoxic critically ill patients 
and may provide an axis for future interventions aimed at 
manipulating hypoxia tolerance in adults.
As well as being a key component in the maintenance 
of vascular tone, nitric oxide (NO) is a fundamental 
cellular messenger with an important role in the regu  la-
tion of fetal and adult biology. Fetal levels of NO 
metabolites are raised in the presence of intrauterine 
growth retardation, particularly when fetal oxygenation is 
compromised [26]. Not only does hypoxia stimulate 
increased release of NO from vascular endothelium, but 
under conditions of cellular hypoxia, mitochondria 
them  selves can produce NO, which may represent part of 
the cellular hypoxia-sensing apparatus [27]. Th  e  potential 
signiﬁ   cance of this metabolite is highlighted in high-
altitude resident Tibetans, whose circulating concentra-
tions of bioactive NO products are 10 times higher than 
those of low-altitude dwellers [28]. In fact, the authors of 
this study stated that ‘the plasma nitrite and nitrate 
concentrations of Tibetans were unprecedented for 
healthy people and that average concentrations exceeded 
those typically seen in septic shock patients’ [28]. Th  is 
poses an interesting conundrum. In the Tibetans, high 
circulating NO metabolites appear to be beneﬁ  cial, 
whereas in critically ill patients, it may represent a 
maladaptive phenomenon that leads to circulatory catas-
trophe. Interestingly, HbF displays an NO-scavenging 
eﬀ  ect that is greater than that of adult hemoglobin [29], 
which may account for the apparent circulatory stability 
within the fetus in the face of severe hypoxemia.
In utero to intensive care
Th  e ability of the fetus to withstand profound and 
sustained hypoxia in utero may serve as a model from 
which to develop strategies to improve survival in 
hypoxemic critically ill adults (Figure 1). With a better 
understanding of the relationship between hypoxemia 
and tissue hypoxia, ‘permissive hypoxemia’ could become 
a realistic possibility in selected patient cohorts. Simply 
adding more oxygen at the top of the oxygen cascade may 
not be the solution to disequilibrium at a tissue level. 
Furthermore, the toxic potential of oxygen is frequently 
understated despite mounting evidence in animal models 
and human studies [30-33]. A recent multicenter cohort 
study of over 6,000 patients who had sustained a non-
traumatic cardiac arrest demonstrated that those patients 
who were hyperoxic (deﬁ  ned as a PaO2 of greater than 
40 kPa) had a signiﬁ  cantly higher in-hospital mortality 
rate when compared with normoxic or hypoxic patients 
[34]. In the current clinical climate of goal-directed 
oxygen delivery, the degree to which chronic hypoxemia 
should be corrected remains unknown. With accumu-
lating evidence that normoxia may not be a prerequisite 
for survival or successful recovery, the possibility of 
permitting selected patients to remain hypoxic conse-
quent upon their disease process may not be as absurd as 
it initially appears. Th   e damage caused by high concen-
trations of inspired oxygen and aggressive mechanical 
ventilation protocols has promoted this philosophy 
among pediatric critical care physicians [35]. With more 
reliable monitors of speciﬁ  c tissue oxygenation, such as 
near-infrared spectroscopy, we might begin to relinquish 
our deep-rooted need to fully correct hypoxemia.
One group of authors has elegantly highlighted how 
rethinking our perceptions of oxygenation has the 
potential to revolutionize patient care [36,37]. In two 
meta-analyses, they questioned the evidence base for the 
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during acute myocardial infarction, reporting a striking 
association between high inspired oxygen concentrations 
and reduced coronary blood ﬂ  ow, greater infarct size, 
and a potentially increased risk of mortality [36,37]. 
Conversely, intracoronary transfer of autologous bone 
marrow cells has already been shown to promote 
improve  ment of left ventricular systolic function after 
acute myocardial infarction [38]. Th   e use of stem cells in 
targeted regenerative medicine is likely to play a major 
part in future interventions. Reprogramming of adult cell 
lines by transduction of transcription factors can 
generate induced pluripotent stem cells (iPSCs). Hypoxia 
not only enhances the generation of iPSCs [39] but also 
promotes the renewal of stem cells via HIF-mediated 
pathways [40]. Is this a window into the body’s own 
attempts at regeneration and repair in response to 
hypoxia, and can we mimic such repair mechanisms?
Owing to an oxygen-carrying capacity greater than that 
of adult hemoglobin, HbF enhances the transport of 
oxygen across the placenta from the maternal circulation. 
Consisting of α2γ2 subunits rather than α2β2 possessed by 
most healthy adults, HbF has a lower aﬃ   nity  for 
2,3-diphosphoglycerate than adult hemoglobin does, 
therefore causing a leftwards-shifted oxygen-hemoglobin 
dissociation curve. Th   is accounts for the greater 
measured SaO2 for any given PaO2 in fetal, as compared 
with maternal, blood. In those born with sickle cell 
disease, HbF production continues in adult life, optimiz-
ing arterial oxygen content. So signiﬁ  cant is the persis-
tence of this fetal mechanism that a low level of HbF in 
sickle cell patients is an independent predictor of early 
mortality [41] and pharmacologically increasing HbF 
concentration with hydroxyurea improves long-term 
outcome in this patient cohort [42], possibly via an NO-
mediated pathway [43]. Humans homozygous for the 
genetic disorder ‘hereditary persistence of fetal hemo-
globin’ express γ-globin only and thus all of their 
circulating hemoglobin is of the fetal species [44]. Th  is 
benign condition also exists in variety of heterozygous 
Figure 1. Therapy for hypoxemic critically ill adults: potential therapeutic targets derived from translational work in fetal and high-
altitude research. CO, carbon monoxide; H2S, hydrogen sulphide; HIF-1, hypoxia-inducible factor 1; PHD, prolyl hydroxylase.
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which β-hemoglobinopathies are prevalent [45]. As the 
presence of high circulating quantities of HbF appears to 
be without detrimental eﬀ  ect, pharmacological reactiva-
tion of the γ-globin and HbF in adult erythroid cells 
during chronic hypoxemia seems feasible. Th  e growth-
modifying cytokine, stem cell factor, in combination with 
erythropoietin, leads to increased production of HbF in 
animal models [46]. Genetic manipulation of the 
switching mechanism between β- and γ-globin at DNA 
transcription or via alteration of γ-globin mRNA trans-
cription, translation, and post-translational events might 
allow adults to revert to a fetal oxygen-carrying modality.
It has been proposed that the multiple organ failure 
witnessed in severe critical illness may represent a 
rudimentary reduction in mitochondrial oxygen con-
sump  tion in order to preserve organs when faced with a 
life-threatening challenge [47]. Th  is is analogous to the 
strategy adopted by the fetus in times of distress and the 
concept may hold the key to an alternative approach to 
managing severe hypoxemia. Hydrogen sulphide (H2S) is 
an endogenously produced signaling molecule that 
belongs to a trio of biological mediators, including NO 
and carbon monoxide (CO), referred to as gasotrans-
mitters [48]. H2S is known to inﬂ  uence cellular metabo-
lism via cytochrome oxidase and carbonic anhydrase and 
interaction with reactive oxygen and nitrogen species 
(leading to free radical scavenging). It also causes activa-
tion of ATP-sensitive potassium (KATP) channels and 
modiﬁ  cation of gene transduction [49]. Low concentra-
tions of H2S exert a cytoprotective eﬀ  ect, whereas higher 
concentrations have the more commonly appreciated 
cytotoxic properties, primarily via mitochondrial failure. 
Th  e relevance of H2S to critical care medicine is that, 
when used in carefully titrated doses, it has the ability to 
induce a state of hibernation in animal models [50-52]. In 
such a state of torpor, the organism undergoes a 
reversible reduction in energy-consuming processes that 
facilitates a reduction in both oxygen uptake and delivery, 
therefore protecting tissues from oxygen deprivation. 
When mice are exposed to H2S gas, they undergo a dose-
related reduction in metabolic, heart, and respiratory 
rates for a period of several hours [50]. Th   is permits the 
tolerance of severe and prolonged hypoxia without 
detrimental eﬀ  ects [53]. Basal H2S production has been 
demonstrated in fetal membranes, and there is a 
signiﬁ  cant up  regulation when the tissues are exposed to 
low levels of oxygen in vitro [54]. Th  is  hypoxia-induced 
elevation in H2S may represent a primitive protective 
mechanism that serves to downregulate metabolism 
during times of stress, a step beyond the simple reduction 
of fetal movements observed following acute oxygen 
deprivation in utero. CO can also protect against hypoxic 
damage by interacting with HIF-1-induced pathways to 
induce a state of ‘suspended animation’ [55]. Further-
more, hypoxia promotes the endogenous produc  tion of 
CO via haem oxygenase-1, a process that prevents 
hypoxic damage through a variety of anti-inﬂ  ammatory 
and anti-apoptotic mechanisms [56]. Th  e question of 
whether humans safely enter a state of reversible suspen-
ded animation remains. Sporadic case reports provide 
circumstantial evidence that prolonged hypothermia and 
hypoxemia can be tolerated without detrimental eﬀ  ects 
[57]. Induced suspended animation has also been 
proposed as a viable strategy following cardiac arrest [50] 
and during severe sepsis [58]. Th   e possibility of pharma-
cologically induced hibernation in the critically ill would 
be as revolutionary as the iron lung, diverting the focus 
of oxygen supply-demand coupling to the latter rather 
than the former.
Th   e pivotal role of HIF in oxygen sensing and hypoxic 
adaptation also makes it a prime target for interventional 
studies. Already, work on speciﬁ  c inhibitors of PHD has 
been shown to induce hypoxic adaption [59]. In combina-
tion with other components of the cellular hypoxic 
response, such as regulators of the NO pathway and 
UCPs, these alternative strategies may avoid therapeutic 
interventions that resort to the administration of toxic 
concentrations of oxygen. Crosstalk between the HIF-1 
transcription pathway and the ROS cascade should 
provide a wealth of targets for future pharmacological 
interventions.
Mastery of human cellular adaptation to hypoxia may 
be feasible in the paradigm of scientiﬁ  cally robust high-
altitude research [60,61]. Th   e inter-individual variation in 
human performance at high altitude [62] mirrors that 
expressed in the hypoxemic environment experienced 
during critical illness. Th  is alternative methodological 
approach to hypoxia research could lead to novel trans-
lational studies in critically ill patients. Exposure of 
healthy individuals to graded ‘doses’ of hypoxia provides 
a platform from which physiological mechanisms of 
adaptation and eﬀ   ects of their perturbation can be 
observed in whole-body systems. It holds further advan-
tage in controlling for the unfavorable ‘signal-to-noise 
ratio’ that is often encountered in the study of patient 
populations with multiple pathologies. Our current 
under  standing of the process of acclimatization to high 
altitude focuses on restoration of normal sea level 
systemic oxygen delivery via increases in minute 
ventilation, cardiac output, and red blood cell mass. 
However, as in survival in utero, the mechanisms that 
separate survivors from non-survivors may lie in the 
cellular control of oxygen consumption via the signaling 
pathways discussed. Indigenous populations living at 
high altitudes have the advantage of lasting biological 
changes as a result of the evolutional pressure exerted by 
hypobaric hypoxia. Th  eir capacity for systemic oxygen 
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lander’ [3,63], thus suggesting more intricate changes 
with thousands of years of evolution, making their 
physiology more akin to that of the fetus.
Conclusions
Human organ systems have developed in an oxygen-
deprived environment during fetal life. Th  is  brief 
develop  mental era is easily forgotten when we consider 
adaptation to hypoxemia yet it may well hold the key to 
our most sophisticated compensatory mechanisms, with 
a potential for reawakening in disease states. Th  e  complex 
network of cellular signaling pathways that act to detect 
hypoxia and preserve cellular functioning in utero may be 
the answer to the failure of the systemic delivery of 
oxygen to tissues. Manipulation of gasotransmitters to 
promote adaptation to hypoxemia may avoid the detri-
mental eﬀ  ects of excessive oxygen administration. All of 
us are triumphant mountaineers of Barcroft’s Everest in 
utero and the sequeale of that expedition may return to 
save us in our hour of need.
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